[go: up one dir, main page]

DE60233231D1 - Ex-vivo-priming zur erzeugung cd40-ligand spezifischer zytotoxischer t-lymphozyten zur behandlung von autoimmun- und allergischen erkrankungen - Google Patents

Ex-vivo-priming zur erzeugung cd40-ligand spezifischer zytotoxischer t-lymphozyten zur behandlung von autoimmun- und allergischen erkrankungen

Info

Publication number
DE60233231D1
DE60233231D1 DE60233231T DE60233231T DE60233231D1 DE 60233231 D1 DE60233231 D1 DE 60233231D1 DE 60233231 T DE60233231 T DE 60233231T DE 60233231 T DE60233231 T DE 60233231T DE 60233231 D1 DE60233231 D1 DE 60233231D1
Authority
DE
Germany
Prior art keywords
ige
specific
ctl
vitro
vivo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60233231T
Other languages
English (en)
Inventor
Zeling Cai
Michael R Jackson
Per A Peterson
Weixing Shi
Yan Kong
Juli Degraw
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
Ortho McNeil Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho McNeil Janssen Pharmaceuticals Inc filed Critical Ortho McNeil Janssen Pharmaceuticals Inc
Application granted granted Critical
Publication of DE60233231D1 publication Critical patent/DE60233231D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/48—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/58—Adhesion molecules, e.g. ICAM, VCAM, CD18 (ligand), CD11 (ligand), CD49 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/50—Coculture with; Conditioned medium produced by invertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
DE60233231T 2001-05-15 2002-05-13 Ex-vivo-priming zur erzeugung cd40-ligand spezifischer zytotoxischer t-lymphozyten zur behandlung von autoimmun- und allergischen erkrankungen Expired - Lifetime DE60233231D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29130001P 2001-05-15 2001-05-15
PCT/US2002/015341 WO2002092773A2 (en) 2001-05-15 2002-05-13 Ex-vivo priming for generating cytotoxic t lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease

Publications (1)

Publication Number Publication Date
DE60233231D1 true DE60233231D1 (de) 2009-09-17

Family

ID=23119750

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60233231T Expired - Lifetime DE60233231D1 (de) 2001-05-15 2002-05-13 Ex-vivo-priming zur erzeugung cd40-ligand spezifischer zytotoxischer t-lymphozyten zur behandlung von autoimmun- und allergischen erkrankungen

Country Status (11)

Country Link
US (10) US7811816B2 (de)
EP (4) EP2107110A3 (de)
JP (2) JP2005516581A (de)
AT (1) ATE438710T1 (de)
AU (1) AU2002308732A1 (de)
CA (1) CA2447593C (de)
DE (1) DE60233231D1 (de)
ES (1) ES2329453T3 (de)
MX (1) MXPA03010507A (de)
PT (1) PT1407004E (de)
WO (1) WO2002092773A2 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2447593C (en) * 2001-05-15 2014-07-08 Ortho-Mcneil Pharmaceutical, Inc. Ex-vivo priming for generating cytotoxic t lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease
AU2002326751A1 (en) * 2001-08-13 2003-03-03 Ige Therapeutics, Inc. Immunoglobulin e vaccines and methods of use thereof
US20080286312A1 (en) * 2002-06-12 2008-11-20 Gavish-Galilee Bio Applications Ltd. Membrane-anchored beta2 microglobulincovalently linked to MHC class I peptide epitopes
EP1677821B1 (de) * 2003-10-17 2013-02-27 Baylor College Of Medicine Verfahren zur verstärkung der cd8+ zytotoxischen t-zell-antworten und zur behandlung von multipler sklerose
FR2883873B1 (fr) 2005-03-31 2009-07-10 Pharmamens Sarl Inhibiteurs d'age
EP2066339B1 (de) 2006-09-18 2014-08-13 The Board Of Trustees Of The University Of Arkansas Zusammensetzungen und verfahren zur verstärkung von immunreaktionen
JP5543207B2 (ja) 2006-10-04 2014-07-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 不活性化された人工抗原提示細胞の調製および細胞治療におけるそれらの使用
NZ585776A (en) 2007-10-30 2012-07-27 Univ Arkansas Compositions and methods of enhancing immune responses to flagellated bacterium
WO2009059298A2 (en) 2007-11-01 2009-05-07 Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancinc immune responses to eimeria
WO2011031757A1 (en) * 2009-09-11 2011-03-17 Centocor Ortho Biotech Inc. Serum markers for identification of cutaneous systemic sclerosis subjects
US8075895B2 (en) * 2009-09-22 2011-12-13 Janssen Pharmaceutica N.V. Identification of antigenic peptides from multiple myeloma cells
CN102811734B (zh) 2010-01-21 2016-02-10 阿肯色大学评议会 增强免疫应答的疫苗载体和方法
EP2365036A1 (de) * 2010-03-12 2011-09-14 Cytec Surface Specialties, S.A. Strahlungshärtbare wässrige Beschichtungszusammensetzungen
ES2753142T3 (es) 2010-06-09 2020-04-07 Univ Arkansas Vacuna y métodos para reducir una infección por Campylobacter
DE102010044131A1 (de) 2010-11-18 2012-05-24 Bayer Schering Pharma Aktiengesellschaft Substituiertes Natrium-1H-pyrazol-5-olat
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
LU91934B1 (en) * 2012-01-25 2013-07-26 Ct De Rech Public Gabriel Lippmann Controlled radical assisted polymerization
EP2812431B1 (de) 2012-02-09 2019-07-17 Baylor College Of Medicine Peptidmischungen zur erzeugung multiviraler ctl mit breiter spezifität
US12188004B2 (en) * 2012-05-08 2025-01-07 The Johns Hopkins University Cancer immunotherapy using transfusions of allogeneic, tumor-specific CD4+ T cells
ES2968398T3 (es) 2013-02-14 2024-05-09 Univ Arkansas Composiciones y métodos para potenciar las respuestas inmunitarias a Eimeria o limitar la infección por Eimeria
KR20240147707A (ko) * 2013-02-20 2024-10-08 리제너론 파아마슈티컬스, 인크. 사람화된 ｔ-세포 보조-수용체를 발현하는 마우스
EP3578190A1 (de) 2013-03-15 2019-12-11 The Board of Trustees of the University of Arkansas Zusammensetzungen und verfahren zur verstärkung der immunreaktionen gegen enterale pathogene
US10716525B2 (en) 2015-08-06 2020-07-21 Covidien Lp System and method for navigating to target and performing procedure on target utilizing fluoroscopic-based local three dimensional volume reconstruction
US10702226B2 (en) 2015-08-06 2020-07-07 Covidien Lp System and method for local three dimensional volume reconstruction using a standard fluoroscope
US10674982B2 (en) 2015-08-06 2020-06-09 Covidien Lp System and method for local three dimensional volume reconstruction using a standard fluoroscope
EP4290238A3 (de) 2015-09-18 2024-09-11 Baylor College of Medicine Identifizierung immunogener antigene aus einem pathogen und korrelation mit klinischer wirksamkeit
TWI843057B (zh) 2016-05-03 2024-05-21 阿肯色州大學董事會 包含免疫刺激性及抗原性多肽的酵母菌疫苗載體以及其使用方法
WO2017216768A1 (en) 2016-06-16 2017-12-21 Association For The Advancement Of Tissue Engineering And Cell Based Technologies And Therapies - A4Tec Dendrimer-derived artificial antigen, methods and uses thereof
US11529190B2 (en) 2017-01-30 2022-12-20 Covidien Lp Enhanced ablation and visualization techniques for percutaneous surgical procedures
EP3638262A4 (de) * 2017-06-16 2021-03-24 Mayo Foundation for Medical Education and Research Materialien und verfahren zur erhöhung der immunreaktion
US10699448B2 (en) 2017-06-29 2020-06-30 Covidien Lp System and method for identifying, marking and navigating to a target using real time two dimensional fluoroscopic data
US10893843B2 (en) 2017-10-10 2021-01-19 Covidien Lp System and method for identifying and marking a target in a fluoroscopic three-dimensional reconstruction
US11364004B2 (en) 2018-02-08 2022-06-21 Covidien Lp System and method for pose estimation of an imaging device and for determining the location of a medical device with respect to a target
US11705238B2 (en) 2018-07-26 2023-07-18 Covidien Lp Systems and methods for providing assistance during surgery
US11877806B2 (en) 2018-12-06 2024-01-23 Covidien Lp Deformable registration of computer-generated airway models to airway trees
US11617493B2 (en) 2018-12-13 2023-04-04 Covidien Lp Thoracic imaging, distance measuring, surgical awareness, and notification system and method
US11801113B2 (en) 2018-12-13 2023-10-31 Covidien Lp Thoracic imaging, distance measuring, and notification system and method
US11357593B2 (en) 2019-01-10 2022-06-14 Covidien Lp Endoscopic imaging with augmented parallax
US11625825B2 (en) 2019-01-30 2023-04-11 Covidien Lp Method for displaying tumor location within endoscopic images
US11744643B2 (en) 2019-02-04 2023-09-05 Covidien Lp Systems and methods facilitating pre-operative prediction of post-operative tissue function
US11627924B2 (en) 2019-09-24 2023-04-18 Covidien Lp Systems and methods for image-guided navigation of percutaneously-inserted devices
US12102298B2 (en) 2019-12-10 2024-10-01 Covidien Lp Lymphatic system tracking
CN111944018B (zh) * 2020-08-28 2022-12-23 深圳市乐土生物医药有限公司 诱导肝癌特异性细胞毒性t淋巴细胞的抗原多肽及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614611A (en) * 1987-12-31 1997-03-25 Tanox Biosystems, Inc. Humanized monoclonal antibodies binding to IgE-bearing B cells but not basophils
US5734023A (en) 1991-11-19 1998-03-31 Anergen Inc. MHC class II β chain/peptide complexes useful in ameliorating deleterious immune responses
US5314813A (en) 1992-02-19 1994-05-24 Scripps Research Institute Drosophila cell lines expressing genes encoding MHC class I antigens and B2-microglobulin and capable of assembling empty complexes and methods of making said cell lines
AU4678993A (en) * 1992-07-16 1994-02-14 Board Of Trustees Of The Leland Stanford Junior University Methods for using dendritic cells to activate t cells
FR2715304B1 (fr) * 1994-01-26 1996-04-26 Merieux Serums Vaccins Pasteur Vaccin anti-allergique.
US5874560A (en) 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US5645837A (en) 1995-01-17 1997-07-08 Thomas Jefferson University Peptides that inhibit T cell activation and methods of using the same
DK0814838T3 (da) 1995-03-08 2003-09-15 Scripps Research Inst Antigenpræsenterende system og aktivering af T-celler
AU5801896A (en) * 1995-05-23 1996-12-11 Scripps Research Institute, The Antigen-specific activation of unprimed cd8+ t cells
EP0934083B1 (de) * 1996-10-23 2009-04-29 The Trustees Of The University Of Pennsylvania Verbesserte impfstoffe
TWI227241B (en) * 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
ES2259478T3 (es) * 1998-09-18 2006-10-01 Dynavax Technologies Corporation Metodos para tratar trastornos asociados con la ige y composiciones para este uso.
EP1123086B1 (de) * 1998-10-20 2010-03-03 Androclus Technologies S.r.l. in liquidazione Künstliche antigen-spezifischen zellen und zugehörige verfahren
US6913749B2 (en) * 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
EP1967206B1 (de) * 2000-08-30 2012-10-10 Pfizer Products Inc. Anti-IgE Vakzine
IL154219A0 (en) * 2000-09-06 2003-07-31 Pharmexa As Method for down-regulating ige
CA2447593C (en) * 2001-05-15 2014-07-08 Ortho-Mcneil Pharmaceutical, Inc. Ex-vivo priming for generating cytotoxic t lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease
AU2002326751A1 (en) * 2001-08-13 2003-03-03 Ige Therapeutics, Inc. Immunoglobulin e vaccines and methods of use thereof

Also Published As

Publication number Publication date
US8106153B2 (en) 2012-01-31
ATE438710T1 (de) 2009-08-15
CA2447593C (en) 2014-07-08
EP2107110A2 (de) 2009-10-07
US8133728B2 (en) 2012-03-13
EP1407004A2 (de) 2004-04-14
US20110027301A1 (en) 2011-02-03
US7842501B2 (en) 2010-11-30
EP2330187A2 (de) 2011-06-08
EP2687593A1 (de) 2014-01-22
JP5247547B2 (ja) 2013-07-24
WO2002092773A3 (en) 2003-11-06
US20110015370A1 (en) 2011-01-20
US20110065186A1 (en) 2011-03-17
US20110021747A1 (en) 2011-01-27
EP2107110A3 (de) 2011-10-26
EP2330187B1 (de) 2016-07-27
US20110065180A1 (en) 2011-03-17
US20110020309A1 (en) 2011-01-27
EP2330187A3 (de) 2011-09-21
US20110065187A1 (en) 2011-03-17
US8084256B2 (en) 2011-12-27
JP2009165482A (ja) 2009-07-30
PT1407004E (pt) 2009-08-31
AU2002308732A1 (en) 2002-11-25
US20070098734A1 (en) 2007-05-03
JP2005516581A (ja) 2005-06-09
CA2447593A1 (en) 2002-11-21
EP1407004A4 (de) 2004-07-21
US8133972B2 (en) 2012-03-13
WO2002092773A2 (en) 2002-11-21
US8084253B2 (en) 2011-12-27
US7811816B2 (en) 2010-10-12
US20030170212A1 (en) 2003-09-11
EP1407004B1 (de) 2009-08-05
ES2329453T3 (es) 2009-11-26
US8133726B2 (en) 2012-03-13
US20090202506A1 (en) 2009-08-13
MXPA03010507A (es) 2005-07-25

Similar Documents

Publication Publication Date Title
DE60233231D1 (de) Ex-vivo-priming zur erzeugung cd40-ligand spezifischer zytotoxischer t-lymphozyten zur behandlung von autoimmun- und allergischen erkrankungen
Zhu et al. CD4 T helper cell subsets and related human immunological disorders
Lombardi et al. CD8α+ β− and CD8α+ β+ plasmacytoid dendritic cells induce Foxp3+ regulatory T cells and prevent the induction of airway hyper-reactivity
Tezuka et al. Regulation of IgA production by intestinal dendritic cells and related cells
Kunisawa et al. Immunological commonalities and distinctions between airway and digestive immunity
Jutel et al. Immunological mechanisms of allergen‐specific immunotherapy
Taylor et al. Mechanisms of immune suppression by interleukin‐10 and transforming growth factor‐β: the role of T regulatory cells
Kim et al. Fundamental role of dendritic cells in inducing Th2 responses
Gilles et al. Pollen allergens do not come alone: Pollen associated lipid mediators (PALMS) shift the human immue systems towards a TH 2-dominated response
Verhagen et al. Mechanisms of allergen-specific immunotherapy: T-regulatory cells and more
Gieni et al. Allergen-specific modulation of cytokine synthesis patterns and IgE responses in vivo with chemically modified allergen.
Wilcock et al. IgE-facilitated antigen presentation: role in allergy and the influence of allergen immunotherapy
Taylor et al. T regulatory cells and allergy
Haque et al. The role of TGFβ and other cytokines in regulating mast cell functions in allergic inflammation
Zheng et al. Generation of human Th1‐like regulatory CD4+ T cells by an intrinsic IFN‐γ‐and T‐bet‐dependent pathway
Nahar et al. Regression and eradication of triple-negative breast carcinoma in 4T1 mouse model by combination immunotherapies
Byun et al. Rosiglitazone-mediated dendritic cells ameliorate collagen-induced arthritis in mice
To et al. Therapeutic Efficacy of Th1 and Th2 L‐selectin− CD4+ Tumor‐Reactive T Cells
Shibuya et al. Differential effects of IFN-α on the expression of various TH2 cytokines in human CD4+ T cells
Magnan et al. Venom immunotherapy induces monocyte activation
Bellinghausen et al. Analysis of allergic immune responses in humanized mice
Liu et al. Administration of polysaccharides from Antrodia camphorata modulates dendritic cell function and alleviates allergen‐induced T helper type 2 responses in a mouse model of asthma
Novak Targeting dendritic cells in allergen immunotherapy
Shanmugasundaram et al. Regulatory T cell properties of thymic CD4+ CD25+ cells in ducks
Li et al. Immunosenescence: A new direction in anti-aging research

Legal Events

Date Code Title Description
8364 No opposition during term of opposition